The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States
Authors:
Open Access
- 1 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (11) , 1294-1306
Abstract
(See the editorial commentary by Lo Re III, on pages 1307–1309 .) Background. Hepatitis B virus (HBV) continues to cause significant morbidity and mortality in the United States. Current guidelines suggest screening populations with a prevalence of ≥2%. Our objective was to determine whether this screening threshold is cost-effective and whether screening lower-prevalence populations might also be cost-effective. Methods. We developed a Markov state transition model to examine screening of asymptomatic outpatients in the United States. The base case was a 35-year-old man living in a region with an HBV infection prevalence of 2%. Interventions (versus no screening) included screening for Hepatitis B surface antigen followed by treatment of appropriate patients with (1) pegylated interferon-α2a for 48 weeks, (2) a low-cost nucleoside or nucleotide agent with a high rate of developing viral resistance for 48 weeks, (3) prolonged treatment with low-cost, high-resistance nucleoside or nucleotide, or (4) prolonged treatment with a high-cost nucleoside or nucleotide with a low rate of developing viral resistance. Effectiveness was measured in quality-adjusted life years (QALYs) and costs in 2008 US dollars. Results. Screening followed by treatment with a low-cost, high-resistance nucleoside or nucleotide was cost-effective ($29,230 per QALY). Sensitivity analyses revealed that screening costs <$50,000 per QALY in extremely low-risk populations unless the prevalence of chronic HBV infection is <.3%. Conclusions. The 2% threshold for prevalence of chronic HBV infection in current Centers for Disease Control and Prevention/US Public Health Service screening guidelines is cost-effective. Furthermore, screening of adults in the United States in lower-prevalence populations (eg, as low as .3%) also is likely to be cost-effective, suggesting that current health policy should be reconsidered.Keywords
This publication has 50 references indexed in Scilit:
- Systematic Review: Health-State Utilities in Liver Disease: A Systematic ReviewMedical Decision Making, 2008
- The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in SingaporeJournal of Viral Hepatitis, 2007
- Cost Effectiveness of Hepatitis B Vaccination at HIV Counseling and Testing SitesAmerican Journal of Preventive Medicine, 2006
- Cofactors associated with liver disease mortality in an HBsAg‐positive Mediterranean cohort: 20 years of follow‐upInternational Journal of Cancer, 2006
- Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral LoadGastroenterology, 2006
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Assessment of Utilities and Health-Related Quality of Life in Patients With Chronic Liver DiseaseAmerican Journal of Gastroenterology, 2001
- Long-term follow-up study of asymptomatic hbsag-positive voluntary blood donors in austria: A clinical and histologic evaluation of 242 casesHepatology, 1987
- Probabilistic Sensitivity Analysis Using Monte Carlo SimulationMedical Decision Making, 1985
- Decision Maker 3.0Medical Decision Making, 1983